TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of CF established by sweat chloride \> 60 mmol/L.~2. Age older than 18 years.~3. History of chronic daily sputum production.~4. Currently on a home therapeutic regimen that includes some form of airway clearance performed with a HFCWO device at least once daily that also includes concomitant use of an inhaled mucolytic and inhaled bronchodilator.~5. FVC and FEV1 \> 40%-predicted, and with stable lung function (no greater than a 10% variation in lung function parameters over the preceding 3 months).~6. Evaluated at the University of Minnesota CF Center 3 or more times in the preceding 12 months.~Exclusion criteria:~1. Hospitalization for CF pulmonary complications in the 2 months preceding enrollment.~2. Hemoptysis \> 60 cc in a single episode in the 4 weeks preceding enrollment.~3. Chest pain requiring use of narcotic for pain control.~4. Current participation in another clinical trial.~5. Use of intravenous antibiotics for CF respiratory complications in the 2 months preceding enrollment.~6. No prior experience using HFCWO devices for airway clearance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HFCWC with higher pressure/variable frequency settings (Type: ACTIVE_COMPARATOR): Half patients randomly assigned to perform HFCWC therapy first with a higher pressure/variable frequency protocol. This entailed performing a 30 minute session with pressure of 10 and 5 minutes each at frequencies of 8,9, and 10 Hz followed by pressure of 6 and 5 minutes each at frequencies of 18, 19, and 20 Hz. This group subsequently crossed-over to the lower-pressure/mid-frequency HFCWC protocol after a washout period of 2 days. This entailed performing a HFCWC session using a pressure of 5 and frequency of 12 Hz for the entire 30 minute session. The other half of subjects were randomly assigned to perform the lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency after the 2 day washout period
- HFCWC with lower pressure/mid-frequency settings (Type: ACTIVE_COMPARATOR): lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Herbal Formula Corresponding to Syndrome in Treating Post Percutaneous Coronary Intervention (PCI) Patients With Coronary Heart Disease (CHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18-75 years old~* Clinical diagnosis of coronary heart disease (confirmed by coronary angiography)~* Successfully received interventional therapy (PTCA or PCI)~* belong to TCM blood-stasis syndrome~* Must be able to swallow tablets~* Able to give written informed consent~Exclusion Criteria:~* Symptomatic congestive heart failure(New York Heart Association class III-IV)~* Females during pregnancy or lactation~* Serious dysfunction in important organs (liver, lung, kidney，et al)~* Use of concomitant Chinese herbal medicine~* Already attend other clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Xuefu Zhuyu Capsules (Type: EXPERIMENTAL): None
- Sheng Mai Capsules (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of functional constipation with Rome II criteria~* General stool type belongs to Type 1 to 4 according to Bristol Stool Form Scale~* Complete spontaneous bowel movement≦2 movements per week~Exclusion Criteria:~* Anti-diarrhoeal therapy~* Drug-induced constipation~* Medical history of important bowel pathology, such as inflammatory bowel disease, congenital or acquired megacolon / megarectum~* Medical history of previous abdominal surgery~* Taking chronic medications that contain any kind of herbs, mineral, or specific vitamin supplements~* Medical history of carbohydrate malabsorption, hormonal disorder, cancer, diabetes mellitus, hypothyroidism, asthma, renal impairment and/or any other serious diseases~* History of laxative abuse~* History of allergy to Chinese herbal medicine~* Psychiatric or addictive disorders~* Pregnancy or breast-feeding~* Any other serious diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MaZiRenWan (MZRW) Low dose (Type: EXPERIMENTAL): MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks
- MaZiRenWan (MZRW) Median dose (Type: EXPERIMENTAL): MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks
- MaZiRenWan (MZRW) High dose (Type: EXPERIMENTAL): MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who had a kidney transplant performed greater than or equal to 28 days prior to enrollment~* At least 1 identified, suitably matched Posoleucel (ALVR105) cell line for infusion is available.~* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.~* Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.~Exclusion Criteria:~* Undergone allogeneic hematopoietic cell transplantation~* Evidence or history of graft versus host disease (GVHD) or cytokine release syndrome (CRS).~* Uncontrolled or progressive bacterial or fungal infections~* Known or presumed pneumonia~* Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone dose \>0.5 mg/kg/day or equivalent).~* Pregnant or lactating or planning to become pregnant.~* Weight \<40 kg.~* Patients who received, or planned to receive abatacept or belatacept, within 3 months of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Posoleucel (Type: EXPERIMENTAL): Arm 1: Regimen A
- Posoleucel and Placebo (Type: EXPERIMENTAL): Arm 2: Regimen B
- Placebo (Type: PLACEBO_COMPARATOR): Arm 3: Regimen A

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Activity and Metformin Intervention in Obese Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Obese adolescents defined as BMI greater than the 95th percentile for age and gender~* Metformin naive subjects~Exclusion Criteria:~* Elevated fasting plasma glucose ≥ 6.0 mmol/L~* 2 hour plasma glucose ≥ 11.1 mmol/L after a standard glucose load~* A1C \> 6.0%~* Medication other than over the counter drugs, oral contraceptive pill or thyroid hormone replacement~* Smoking~* Pregnancy~* Renal insufficiency (serum creatinine \> the upper limit of normal)~* Hepatic dysfunction (\> 1.5 times the upper limit of normal for AST and ALT)~* Latex Allergy~* Hypersensitivity to metformin or its ingredients~* Breast feeding~* Subjects with a history of lactic acidosis~* Abnormal creatinine clearance~* HIV, HBV, and HCV infections~* Drug and alcohol abuse~* Severe mental disorders~* Subjects who are planning radiologic exams involving in i.v. injection of iodinated contract materials~* Participation in another clinical trial~* Significant history or presence of cardiovascular, pulmonary, gastrointestinal, immunologic, endocrine, neurologic disorders~* Malignant diseases~* Previous exposure to any pharmaceutical antidiabetic agent

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- Metformin, Standard exercise (Type: ACTIVE_COMPARATOR): Lifestyle intervention with metformin and standard exercise program.
- Placebo, Standard exercise (Type: PLACEBO_COMPARATOR): Lifestyle intervention with placebo and standard exercise program
- Metformin, Intensive exercise (Type: ACTIVE_COMPARATOR): Lifestyle intervention with metformin and intensive exercise
- Placebo, Intensive exercise (Type: PLACEBO_COMPARATOR): Lifestyle intervention with placebo and intensive exercise program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of severe hemophilia A defined as \<1% FVIII:C documented in medical records.~* Males between 18 and 65 years of age (Parts 1 and 2).~* Males between 12 and 65 years of age (Part 3).~* Subjects who have received or are currently receiving FVIII products (plasma-derived and/or recombinant FVIII) and have had \>150 exposure days (EDs) with a FVIII product~* Written informed consent for study participation obtained before undergoing any study specific procedures.~Exclusion Criteria:~* Any history of or current FVIII inhibitors~* Any first order family history of FVIII inhibitors~* Use of an Investigational Medicinal Product within 30 days prior to the first rVIII-SingleChain administration.~* Administration of any cryoprecipitate, whole blood or plasma within 30 days prior to administration of rVIII-SingleChain or reference product.~* Known hypersensitivity (allergic reaction or anaphylaxis) to any FVIII product or hamster protein.~* Any known congenital or acquired coagulation disorder other than congenital FVIII deficiency.~* Platelet count \< 100,000/µL at screening.~* Human immunodeficiency virus (HIV) positive subjects with a CD4 count \< 200/mm3, in their medical history or at screening if available results are older than one year. (HIV positive subjects may participate in the study and antiviral therapy are permitted, at the discretion of the Investigator).~* Subject currently receiving IV immunomodulating agents such as immunoglobulin or chronic systemic corticosteroid treatment.~* Subject with serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) values \> 5 times (x) the upper limit of normal (ULN) at Screening.~* Subjects with serum creatinine values \> 2 x ULN at Screening.~* Evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction and arterial embolus within 3 months prior to Day 1.~* Experienced life-threatening bleeding episode or had major surgery or an orthopedic surgical procedure during the 3 months prior to Day 1.

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Recombinant Factor VIII (rFVIII) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Disease Criteria~* Acute leukemia or chronic myelogenous leukemia in blastic crisis or accelerated phase, not in remission at the time of transplant~* Myelodysplastic syndrome, with more than 5% blasts in bone marrow at the time of transplant~* Hodgkin and Non-Hodgkin Lymphomas: Not in CR in PET scan or CT scan before transplant, or relapsed within 1 year from previous remission~* CLL not in remission~* Multiple Myeloma, not in remission~* Suitable donor available (related or unrelated)~Age, Organ Function Criteria~* Age: ≤ 70 years~* Cardiac: LV Ejection Fraction ≥ 40% by MUGA or Echocardiogram~* Pulmonary: FEV1 and FVC ≥ 40% predicted, and DLCO (corrected for hemoglobin) ≥ 40% of predicted~* Renal: Adult population: serum creatinine ≤ 1.0 mg/dL (if serum creatinine \> 1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be \> 60 mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease equation)~* Renal: Pediatric population: serum creatinine clearance ≥ 90 ml/min/1.73 m2 as calculated by the Schwartz formula for estimated GFR~* Hepatic: serum total bilirubin ≤ 2.0 mg/dl and AST / ALT ≤ ULN x 4~* Performance status: Karnofsky ≥ 70%~Exclusion Criteria:~* Other active life-threatening cancer requiring treatment other than allo-HSCT~* HIV1 or HIV2 positive~* Uncontrolled medical or psychiatric disorder~* Uncontrolled viral or fungal infection~* Active CNS leukemia~* Non-compliant to medications~* No appropriate caregivers identified

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Clo/BU4 (Type: EXPERIMENTAL): Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.~After pre-conditioning, subjects will receive a peripheral blood stem cell transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: KRN125 for Mobilization of Hematopoietic Stem Cells

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese subjects aged 20 to 55 years or younger at the submission of the written informed consent form~* Women weighing 40 kg or more and 80 kg or less and men weighing 45 kg or more and 80 kg or less at the time of the preliminary examination~Exclusion Criteria:~* Subjects with a current medical history or who have been judged to be inappropriate for the study (e.g., significant neurological, hepatic, renal, endocrine, cardiovascular, blood, gastrointestinal, respiratory, and metabolic diseases, malignancies, myeloproliferative disorder, or psychiatric disorders)~* Individuals with alcohol or drug dependence, or individuals who have not tested negative for all drugs of abuse in the preliminary test~* Subjects with a history or current history of drug allergy or symptomatic allergy~* .Active infection or history of recurrent infection- However, only patients who are HBsantibody-positive by hepatitis B vaccination and whose HBV-DNA is less than the lower limit of quantitation will be allowed to participate in this study.~* Subjects who used drugs within 2 weeks before administration of the investigational drug.~* Subjects who have had at least 200 mL of blood drawn within 3 months before administration of the investigational drug.~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- KRN125 (Type: EXPERIMENTAL): Single SC administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Muscle Relaxation Reversal on the Success Rate of Motor Evoked Potential Recording

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age range from 18 to 65 years old~* American Society of Anesthesiologists (ASA) physical status I to II~Exclusion Criteria:~* BMI ≥35 kg/m-2~* History of epilepsy or use of antiepileptic drugs~* Personal history or family history of malignant hyperthermia~* Allergies to sugammadex; NMBs or other medication(s) used during general anesthesia~* Hemoglobin \<110 g/L~* TceMEP stimulation or recorded site infection~* Preoperative neurological dysfunction in both upper extremities~* Cardiac pacemaker~* Pregnancy and lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sugammadex group (Type: EXPERIMENTAL): None
- control group (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject who signed the written consent form by themselves, protectors or legal representatives prior to the clinical trial after the person in charge explained fully about objectives, procedure and the characteristics of the study drug.~2. Patient aged 18 to 75~3. Patient with pathologically-confirmed, advanced pancreatic cancer~4. ECOG scale (ECOG-PS) ≤2 (Appendix 4. Performance status scale/score)~5. Patient with anticipated survival period of more than 3 months~6. Patient with progressed disease after Gemcitabine-based primary anti-cancer chemotherapy~7. Patient whose blood test, renal function test and liver function test results meet the following conditions.~Exclusion Criteria:~1. Patient with the medical history of immunodeficiency or autoimmune disease that could be aggravated by immunotherapy (examples: rheumatoid arthritis, systemic lupus erythematosus, vasculitis, multiple sclerosis, adolescent Insulin-Dependent Diabetes Mellitus, etc.)~2. Confirmed immunodeficient patient~3. Patient with the history of cancer other than skin cancer, local prostate cancer or carcinoma in situ of cervix within the last 5 years of the start of study~4. Patient who has received systemic anti-angiogenic agent~5. Patient who has received a chemotherapy other than Gemcitabine based chemotherapy~6. Obvious myocardial failure or uncontrolled arterial hypertension~7. Patient who has experienced serious allergy (judged by the investigator)~8. Patient with serious psychological disease (judged by the investigator)~9. Pregnant woman, breast-feeding woman or woman who want to be pregnant during the trial period~10. Patient who has participated in another clinical trial within the last 4 weeks of the start of study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Immuncell-LC group (Type: EXPERIMENTAL): Intravenous dripping of 200 ml (109\~2 1010 lymphocytes/60 kg adult) for 1 hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be between the ages of 18 to 64~* Meet DSM-IV criteria for schizophrenia or schizoaffective disorder~* Sleep difficulties at least 2x per week in the preceding month~* Be on a stable dose of antipsychotic medication~* Symptomatically stable in the last 2 months~* English speaking.~Exclusion Criteria:~* Meet criteria for current alcohol or other substance dependence~* A history of dementia, mental retardation or other neurological disorder~* Not capable of giving informed consent for participation in this study.~* Ongoing pregnancy~* Known sensitivity to zopiclone.~* Insomnia associated with medical disorders likely to impair sleep.~* Use of any medication that affects sleep/wake function (other than antipsychotic medication), within the past 2 weeks or within a time period that is less than 7 half-lives since last use of the medication.~* Lack of sleep benefit from previous adequate eszopiclone treatment~* History of clinically significant hepatic impairment.~* Subject is taking a potent cytochrome p450 3A4 inhibitor medication (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) and is unwilling or it is clinically contraindicated to stop the medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Eszopiclone Group (Type: EXPERIMENTAL): Participants assigned to this arm will receive Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
- Placebo Group (Type: PLACEBO_COMPARATOR): Participants assigned to this arm will receive placebo (an inactive substance or a sugar pill) to be taken each night for all weeks of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete